BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

AstraZeneca to Launch Sodium Zirconium Cyclosilicate Suspension In November 2025

Synopsis:


AstraZeneca Pharma India will launch sodium zirconium cyclosilicate powder for oral suspension in November 2025, following CDSCO approval to import and market 5 g and 10 g strengths in India. The clearance enables regulated distribution through authorised pharmaceutical channels.


Source:
AstraZeneca Pharma India Limited Press Release (NSE Exchange Filings) | Published on Oct 15, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

AstraZeneca Pharma India News Today

As quoted in the press release from AstraZeneca Pharma India (NSE Exchange Filings), the company will introduce sodium zirconium cyclosilicate (SZC) powder for oral suspension in November 2025. The product has received regulatory permission from the Central Drugs Standard Control Organisation (CDSCO) for two dosage strengths—5 g and 10 g.

The approval allows AstraZeneca to distribute the formulation through authorised medical channels. The therapeutic compound addresses the treatment of hyperkalaemia, following the required pharmaceutical and import standards.

Also read: Marksans Pharma UK Regulatory Approval Adds Clonidine Formulations

Key Takeaway

  • AstraZeneca Pharma India to launch sodium zirconium cyclosilicate powder for oral suspension in November 2025.

  • CDSCO approval covers 5 g and 10 g dosage strengths.

  • Regulatory clearance obtained for import and marketing in India.

  • AstraZeneca's share price was tracked at ₹ 9,140.00 on 15 October 2025.

  • Information verified through National Stock Exchange (NSE) filings.

Also read: Adani Green Operationalises 50 MW Solar Project At Khavda, Gujarat

ASTRAZENECA PHARMA IND LT

Trade

9090-58.50 (-0.63 %)

Updated - 16 October 2025
9233.00day high
DAY HIGH
9085.50day low
DAY LOW
7740
VOLUME (BSE)

Regulatory Approval and Product Details

In March 2025, AstraZeneca Pharma India obtained authorisation from the CDSCO to import and market SZC powder for oral suspension. The clearance covers both 5 g and 10 g strengths.

Sodium zirconium cyclosilicate is a non-absorbed, inorganic compound that binds potassium ions in the gastrointestinal tract, reducing serum potassium concentration. Internationally, the medicine is supplied under the trade name Lokelma.

The company has confirmed compliance with all statutory and quality requirements under Indian drug-control procedures.

Product Specification Table

Parameter

Detail

Product

Sodium Zirconium Cyclosilicate (SZC)

Formulation

Powder for oral suspension

Dosage Strengths

5 g and 10 g

Indication

Treatment of hyperkalaemia

Regulatory Authority

Central Drugs Standard Control Organisation (CDSCO)

Launch Timeline

November 2025

Source

National Stock Exchange (NSE) / Company Press Release

Clinical and Operational Overview

AstraZeneca Pharma India has completed the procedural steps associated with quality validation, distribution planning, and storage certification.

Clinical data from international submissions describe SZC as a selective potassium-binding compound used in adults with hyperkalaemia. The organisation has secured permission to conduct Phase IV studies under Indian oversight to record safety and effectiveness outcomes.

Market Reaction and AstraZeneca Share Price Movement

As of 15 October 2025, 15:30 PM IST, AstraZeneca Pharma India’s share price on the NSE stood at ₹ 9,140.00, an increase of ₹ 18.50 (0.20 %) on the day.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text